Antineoplastic Therapy Use in Patients with Advanced Cancer Admitted to an Acute Palliative Care Unit at a Comprehensive Cancer Center: a Simultaneous Care Model

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2010 Feb 18

PMID 20162701

Citations 21

Authors

David Hui

Ahmed Elsayem

Zhijun Li

Maxine De La Cruz

J Lynn Palmer

Eduardo Bruera

Affiliations

Soon will be listed here.

Abstract

Background: Cancer patients admitted to a palliative care unit generally have a poor prognosis. The role of antineoplastic therapy (ANT) in these patients remains controversial. In the current study, the authors examined the frequency and predictors associated with ANT use in hospitalized patients who required admission to an acute palliative care unit (APCU).

Methods: Included in the study were all 2604 patients admitted over a 5-year period to a 12-bed APCU located within a National Cancer Institute comprehensive cancer center, in which patients had access to both palliative care and ANT. Institutional databases were used to retrospectively retrieve data regarding patient demographics, cancer diagnosis, ANT use, length of hospital stay, and survival from time of admission.

Results: The median hospital stay was 11 days, and the median survival was 22 days. During hospitalization, 435 patients (17%) received ANT, including chemotherapy (N = 297; 11%), hormonal agents (N = 54; 2%), and targeted therapy (N = 155; 6%). No significant change in the frequency of ANT use was detected over the 5-year period. Multivariate logistic regression analysis revealed that younger age, specific cancer diagnoses, and longer admissions were independently associated with ANT use.

Conclusions: The use of ANT during hospitalization that included an APCU stay was limited to a small percentage of patients and did not increase over time. ANT use was associated with younger age, specific cancer diagnoses, and longer admissions. The APCU facilitates simultaneous care for patients receiving ANT.

Citing Articles

A month of diagnostic imaging studies in an acute supportive/palliative care unit.

Mercadante S, Grassi Y, Cascio A Support Care Cancer. 2024; 32(11):741.

PMID: 39436418 DOI: 10.1007/s00520-024-08948-8.

FAM46B suppresses proliferation, migration and invasion of non-small cell lung cancer via β-catenin/MMP7 signaling.

Sang H, Wu S, Chen X, Cheng S, Li Q Transl Cancer Res. 2022; 8(4):1497-1505.

PMID: 35116892 PMC: 8798448. DOI: 10.21037/tcr.2019.07.27.

Models of Palliative Care Delivery for Patients With Cancer.

Hui D, Bruera E J Clin Oncol. 2020; 38(9):852-865.

PMID: 32023157 PMC: 7082156. DOI: 10.1200/JCO.18.02123.

Association between palliative care and end-of-Life care for patients with hematological malignancies: A population-based study.

Chiang J, Lee Y, Kao Y Medicine (Baltimore). 2019; 98(40):e17395.

PMID: 31577748 PMC: 6783235. DOI: 10.1097/MD.0000000000017395.

Combined effects of Lenvatinib and iodine-131 on cell apoptosis in nasopharyngeal carcinoma through inducing endoplasmic reticulum stress.

Wang G, Zhuang J, Ni J, Ye Y, He S, Xia W Exp Ther Med. 2018; 16(4):3325-3332.

PMID: 30233679 PMC: 6143866. DOI: 10.3892/etm.2018.6652.

References

Meyers F, Linder J, Beckett L, Christensen S, Blais J, Gandara D . Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care. J Pain Symptom Manage. 2004; 28(6):548-56. DOI: 10.1016/j.jpainsymman.2004.03.002. View

Rees E, Hardy J, Ling J, Broadley K, AHern R . The use of the Edmonton Symptom Assessment Scale (ESAS) within a palliative care unit in the UK. Palliat Med. 1998; 12(2):75-82. DOI: 10.1191/026921698674135173. View

Earle C, Park E, Lai B, Weeks J, Ayanian J, Block S . Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol. 2003; 21(6):1133-8. DOI: 10.1200/JCO.2003.03.059. View

. Cancer care during the last phase of life. J Clin Oncol. 1998; 16(5):1986-96. DOI: 10.1200/JCO.1998.16.5.1986. View

Moro C, Brunelli C, Miccinesi G, Fallai M, Morino P, Piazza M . Edmonton symptom assessment scale: Italian validation in two palliative care settings. Support Care Cancer. 2005; 14(1):30-7. DOI: 10.1007/s00520-005-0834-3. View

Lamont E, Christakis N . Physician factors in the timing of cancer patient referral to hospice palliative care. Cancer. 2002; 94(10):2733-7. DOI: 10.1002/cncr.10530. View

Doyle C, Crump M, Pintilie M, Oza A . Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol. 2001; 19(5):1266-74. DOI: 10.1200/JCO.2001.19.5.1266. View

Browner I, Carducci M . Palliative chemotherapy: historical perspective, applications, and controversies. Semin Oncol. 2005; 32(2):145-55. DOI: 10.1053/j.seminoncol.2004.11.014. View

Lagman R, Walsh D . Integration of palliative medicine into comprehensive cancer care. Semin Oncol. 2005; 32(2):134-8. DOI: 10.1053/j.seminoncol.2004.11.015. View

10.

McNiff K, Neuss M, Jacobson J, Eisenberg P, Kadlubek P, Simone J . Measuring supportive care in medical oncology practice: lessons learned from the quality oncology practice initiative. J Clin Oncol. 2008; 26(23):3832-7. DOI: 10.1200/JCO.2008.16.8674. View

11.

Ford D, Nietert P, Zapka J, Zoller J, Silvestri G . Barriers to hospice enrollment among lung cancer patients: a survey of family members and physicians. Palliat Support Care. 2008; 6(4):357-62. DOI: 10.1017/S1478951508000564. View

12.

Harrington S, Smith T . The role of chemotherapy at the end of life: "when is enough, enough?". JAMA. 2008; 299(22):2667-78. PMC: 3099412. DOI: 10.1001/jama.299.22.2667. View

13.

Mintzer D, Zagrabbe K . On how increasing numbers of newer cancer therapies further delay referral to hospice: the increasing palliative care imperative. Am J Hosp Palliat Care. 2007; 24(2):126-30. DOI: 10.1177/1049909106297363. View

14.

Zimmerman J, Kramer A, McNair D, Malila F . Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients. Crit Care Med. 2006; 34(5):1297-310. DOI: 10.1097/01.CCM.0000215112.84523.F0. View

15.

Golan H, Bielorai B, Grebler D, Izraeli S, Rechavi G, Toren A . Integration of a palliative and terminal care center into a comprehensive pediatric oncology department. Pediatr Blood Cancer. 2008; 50(5):949-55. DOI: 10.1002/pbc.21476. View

16.

Lagman R, Rivera N, Walsh D, LeGrand S, Davis M . Acute inpatient palliative medicine in a cancer center: clinical problems and medical interventions--a prospective study. Am J Hosp Palliat Care. 2007; 24(1):20-8. DOI: 10.1177/1049909106295292. View

17.

Elsayem A, Swint K, Fisch M, Palmer J, Reddy S, Walker P . Palliative care inpatient service in a comprehensive cancer center: clinical and financial outcomes. J Clin Oncol. 2004; 22(10):2008-14. DOI: 10.1200/JCO.2004.11.003. View

18.

Koedoot C, de Haes J, Heisterkamp S, Bakker P, de Graeff A, de Haan R . Palliative chemotherapy or watchful waiting? A vignettes study among oncologists. J Clin Oncol. 2002; 20(17):3658-64. DOI: 10.1200/JCO.2002.12.012. View

19.

Lam P, Leung M, Tse C . Identifying prognostic factors for survival in advanced cancer patients: a prospective study. Hong Kong Med J. 2007; 13(6):453-9. View

20.

Sato K, Miyashita M, Morita T, Sanjo M, Shima Y, Uchitomi Y . Quality of end-of-life treatment for cancer patients in general wards and the palliative care unit at a regional cancer center in Japan: a retrospective chart review. Support Care Cancer. 2007; 16(2):113-22. DOI: 10.1007/s00520-007-0332-x. View